Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine

@inproceedings{Zhang2015PharmacologicalCO,
  title={Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine},
  author={Yifan Zhang and Ang{\'e}la Kecsk{\'e}s and Dani{\"e}lle Copmans and M{\'e}lanie Langlois and Alexander D. Crawford and Berten Ceulemans and Lieven Lagae and Peter A. M. de Witte and Camila V. Esguerra},
  booktitle={PloS one},
  year={2015}
}
Dravet syndrome (DS) is one of the most pharmacoresistant and devastating forms of childhood epilepsy syndromes. Distinct de novo mutations in the SCN1A gene are responsible for over 80% of DS cases. While DS is largely resistant to treatment with existing anti-epileptic drugs, promising results have been obtained in clinical trials with human patients treated with the serotonin agonist fenfluramine as an add-on therapeutic. We developed a zebrafish model of DS using morpholino antisense… CONTINUE READING